9/24/2023 0 Comments Netspot nuclear medicine 3 vials![]() It allows a non-invasive and quantitative imaging of cellular and molecular events in patients, giving functional information in contrast to morphological information obtained from conventional imaging techniques like computed tomography (CT) or magnetic resonance imaging (MRI). PET is a commonly used imaging technique in nuclear medicine. These kits allow decentralized tracer production and therefore enable the application of the radiotracer to patients who do not live in the vicinity of a centralized production site. ![]() a kit preparation for 68Ga-labeling of DOTA-TATE (NETSPOT TM, AAA, a Novartis Company, Saint-Genis-Pouilly, France) was approved by the FDA on 1 June 2016. Use of this kit along with an authorized 68Ge/ 68Ga-generator enables on-site preparation of Ga-DOTA-TOC even in small facilities. Also in Europe, a kit preparation for 68Ga-labeling of DOTA-TOC (SomaKit TOC ®, AAA, a Novartis company, Saint-Genis-Pouilly, France) was approved by the European Medicines Agency (EMA) on 8 December 2016. The ready-to-use 68Ga-labeled peptide was already approved in some European countries (Austria, Germany, and France) in 2016 (IASOtoc ®, IASON GmbH, Graz, Austria) and in 2018 (TOCscan ®, ITM AG, München, Germany). Holder of the marketing authorization is the UIHC–PET Imaging Center (University of Iowa Health Care (UIHC)), in Iowa, USA. ![]() On 21 August 2019, Ga-DOTA-TOC was approved by the Food and Drug Administration (FDA) for positron emission tomography (PET) imaging of somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |